Pfizer Non Operating Income Net Other Over Time
| PFE Stock | USD 27.22 0.73 2.76% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Pfizer Performance and Pfizer Correlation. Will Pharmaceuticals sector continue expanding? Could Pfizer diversify its offerings? Factors like these will boost the valuation of Pfizer. Anticipated expansion of Pfizer directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Pfizer data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.21) | Dividend Share 1.72 | Earnings Share 1.36 | Revenue Per Share | Quarterly Revenue Growth (0.01) |
Investors evaluate Pfizer Inc using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Pfizer's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Pfizer's market price to deviate significantly from intrinsic value.
It's important to distinguish between Pfizer's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pfizer should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Pfizer's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Non Operating Income Net Other Analysis
Compare Pfizer Inc and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Non Operating Income Net Other Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN | 2.1 M | 3.5 M | 2 M | (231 K) | (25.3 M) | (12.6 M) | 6.3 M | 24 M | 47.3 M | 249.5 M | 290.7 M | 436.3 M | 179.3 M | 179.3 M | 179.3 M | 206.2 M | 216.5 M |
| IDXX | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.7 M | 2.5 M | 3.7 M | 5.3 M | 1.2 M | 427 K | 586 K | 434 K | 1.1 M | 1.1 M | 1.1 M | 958.5 K | 1.5 M |
| CI | (498 M) | (498 M) | (498 M) | (498 M) | (498 M) | (498 M) | (498 M) | (498 M) | (498 M) | (1.7 B) | 2.6 B | (1.3 B) | 434 M | 434 M | 434 M | 499.1 M | 524.1 M |
| BDX | 37 M | 49 M | 49 M | 51 M | 32 M | 32 M | 19 M | 383 M | 30 M | 30 M | (88 M) | (101 M) | (101 M) | (101 M) | (101 M) | (90.9 M) | (86.4 M) |
| ELAN | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (27.4 M) | 178.3 M | (5 M) | (32 M) | (32 M) | (32 M) | (36.8 M) | (35 M) |
| ARGX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| TAK | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Pfizer Inc and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Non Operating Income Net Other description
My Equities
My Current Equities and Potential Positions
| Pfizer Inc | PFE |
| Classification | Healthcare |
| Business Address | 66 Hudson Boulevard |
| Exchange | New York Stock Exchange |
USD 27.22
Check out Pfizer Performance and Pfizer Correlation. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Pfizer technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.